Dr Reddys Laboratories (RDY) EBITDA (2009 - 2026)

Dr Reddys Laboratories has reported EBITDA for 18 years, with the latest figure at $40.0 million in Q2 2026.

• On a quarterly basis, EBITDA fell 80.43% year-over-year to $40.0 million in Q2 2026; TTM through Jun 2026 was $415.1 million, a 50.53% decrease from a year earlier, with the FY2026 full-year figure at $572.7 million, down 31.98% from the prior year.
• EBITDA was $40.0 million for Q2 2026 at Dr Reddys Laboratories, up from $14.5 million in the prior quarter.
• The five-year high for EBITDA was $221.7 million in Q4 2024, with the low at $14.5 million in Q1 2026.
• Average EBITDA over 5 years is $168.3 million, with a median of $202.3 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2026: EBITDA soared 949.44% in 2023, then sank 92.89% in 2026.
• Over 5 years, EBITDA stood at $151.0 million in 2022, then jumped by 37.33% to $207.4 million in 2023, then climbed by 6.91% to $221.7 million in 2024, then fell by 27.89% to $159.9 million in 2025, then plunged by 75.0% to $40.0 million in 2026.
• The last three EBITDA figures came in at $40.0 million (Q2 2026), $14.5 million (Q1 2026), and $159.9 million (Q4 2025), per Business Quant data.